A Phase 1 interventional study of OPN-019 in Covid19, sponsored by Optinose US Inc.. Terminated at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-02.
Sponsored by Optinose US Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies in COVID-19 with a site in Mexico — 12 open to participants now, 14 under way, 6 of them phase 3. COVID-19 · Mexico.
Among the 198 studies in COVID-19 with a site in Mexico, this one is the 143rd largest by enrollment of the 151 interventional ones that give a count, is one of 57 that started in 2021, is one of 11 in phase 1, and was the 153rd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →12 of the 198 studies in COVID-19 with a site in Mexico are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in Mexico, United States, Argentina and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
Pfizer · Sites in Mexico, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Mexico, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Mexico, United States, Argentina and 21 more countries
Ages 18+
AstraZeneca · Sites in Mexico, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 59 · Phase 3 80 · Phase 4 1
First in 2020; this study’s year is marked. 57 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 200 across the 151 interventional studies, 250 across the 47 observational. Of the 148 that completed or were terminated, 57 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 198 have an industry lead sponsor. The 10 most frequent:
Optinose US Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Optinose US Inc. has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
3 of the studies in COVID-19 with a site in Mexico that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 198 studies in COVID-19 with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine both the magnitude and duration of viral load (copies/mL) reduction after a single dose of OPN-019. The variability associated with viral counts will be utilized to inform the study design of future studies.
A randomized, single dose, adaptive design, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms. Patients will be required to have a score ≤ 2 on the WHO ordinal scale for clinical improvement (Covid-19 Therapeutic Trial Synopsis; Feb 18, 2020). Those meeting the inclusion criteria will be randomized to 1 of 2 arms: OPN-019 (2 sprays per nostril) or SOC. Once randomized, subjects will have baseline nasal and oropharyngeal swabs performed for qRT-PCR viral load and infectious viral particle assessment. The subject will then be administered the study medication. Subsequent nasal and oropharyngeal swabs will be taken at 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, and 24 hours. Cohorts of 10 subjects will be randomized into the study and the results from those subjects will be evaluated to determine if changes in the inclusion criteria or study assessments are required.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
currently has one of the clinical signs suggestive of moderate-to-severe COVID-19 illness:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPN-019
400 mg OPN-019, 2 sprays per nostril (one dose)
Change in nasal viral load over multiple time points
Change in nasal viral load (copies/mL) over multiple time points as measured by qRT-PCR testing of nasal swabs.
Time frame: Baseline, 1 Hour, 3 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours post dosing/randomization
Cumulative viral load over 6, 8, and 12-hour periods in oropharyngeal swab
Compare cumulative viral load (copies/mL) (total) over 6, 8, and 12-hour periods in oropharyngeal swab measured by qRT-PCR
Time frame: 6 Hours, 8 Hours, 12 Hours post Dosing/Randomization
Cumulative amount of Nasal Swab infectious viral particles
Compare cumulative amount of infectious viral particles (copies/mL) between OPN-019 dosed subjects versus SOC control group in nasal swab
Time frame: Baseline, 24 Hours post dosing/randomization
Number of subjects with viral load of <10^6 copies/mL
Compare the number of subjects who reach a viral load (copies/ml) of \<10\^6
Time frame: Baseline, 24 Hours post dosing/randomization
Maximum log reduction in viral load
Compare maximum log reduction in viral load (copies/ml) by qRT-PCR
Time frame: Baseline, 24 Hours post dosing/randomization
Time Comparison-subject virus-free or has viral load of <10^6 copies/ml
Time over which subject is virus-free or has viral load (copies/mL) of \<10\^6 , both as measured by qRT-PCR
Time frame: Baseline, 24 Hours post dosing/randomization
Log viral reduction assessment in subgroups-baseline viral load
Assess log viral reduction in subgroups by baseline viral load (copies/mL)
Time frame: Baseline, 24 Hours post dosing/randomization
Evaluation of Safety by recording the severity of spontaneously reported adverse events (AEs)
Assessment of safety by measuring severity of spontaneously reported AEs using scale with 1=mild, 2=moderate, 3=severe
Time frame: Baseline, 24 Hours post dosing/randomization
Evaluation of Safety measuring vital signs- Blood Pressure
Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)
Time frame: Baseline, 24 Hours post dosing/randomization
Evaluation of Safety measuring vital signs- Pulse
Measure pulse in beats per minute (bpm)
Time frame: Baseline, 24 Hours post dosing/randomization
Evaluation of Safety measuring vital signs- Temperature
Measure temperature in °Fahrenheit (°F)
Time frame: Baseline, 24 Hours post dosing/randomization
Evaluation of Safety measuring vital signs- Respiratory Rate
Measure Respiratory Rate in breaths per minute
Time frame: Baseline, 24 Hours post dosing/randomization
Evaluation of Safety - Monitoring Concomitant Medication Usage
Assessment for safety from the collection of information for concomitant medications usage
Time frame: Baseline, 24 Hours post dosing/randomization
Evaluation of Safety - Study Drug Tolerability
Study Medication Tolerability Questionnaire will be completed by subjects rate the levels of nasal discomfort and unpleasant taste associated with study medication use; study specific measure. The Study Medication Tolerability Questionnaire is administered verbally by a study staff member to the subject. This 11-item score is rated on a 0-100 scale, 0 being "dislike it an extreme amount", and 100 being "like it an extreme amount"
Time frame: 1 Hour Post Dose
Ran from Sep 2021 to primary completion in Nov 2021, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Optinose US Inc.